A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis

BACKGROUND: The combination of rifapentine and moxifloxacin administered daily with other anti-tuberculosis drugs is highly active in mouse models of tuberculosis chemotherapy. The objective of this phase 2 clinical trial was to determine the bactericidal activity, safety, and tolerability of a regi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:PLoS One
Päätekijät: Conde, Marcus B., Mello, Fernanda C. Q., Duarte, Rafael Silva, Cavalcante, Solange C., Rolla, Valeria, Dalcolmo, Margareth, Loredo, Carla, Durovni, Betina, Armstrong, Derek T., Efron, Anne, Barnes, Grace L., Marzinke, Mark A., Savic, Radojka M., Dooley, Kelly E., Cohn, Silvia, Moulton, Lawrence H., Chaisson, Richard E., Dorman, Susan E.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Public Library of Science 2016
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4861335/
https://ncbi.nlm.nih.gov/pubmed/27159505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0154778
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia